86 related articles for article (PubMed ID: 17392710)
1. The disconnection between tumor response and survival.
Mittra I
Nat Clin Pract Oncol; 2007 Apr; 4(4):203. PubMed ID: 17392710
[No Abstract] [Full Text] [Related]
2. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy.
Basuroy UK; Gerner EW
J Biochem; 2006 Jan; 139(1):27-33. PubMed ID: 16428316
[TBL] [Abstract][Full Text] [Related]
3. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs).
Fecker LF; Stockfleth E; Nindl I; Ulrich C; Forschner T; Eberle J
Br J Dermatol; 2007 May; 156 Suppl 3():25-33. PubMed ID: 17488403
[TBL] [Abstract][Full Text] [Related]
4. Assembling a tumor progression model.
Redston M
Methods Mol Biol; 2003; 223():383-401. PubMed ID: 12777741
[No Abstract] [Full Text] [Related]
5. [Intraperitoneal chemotherapy in ovarian carcinoma. Life prolonging in selected patients].
Ottevanger PB
Ned Tijdschr Geneeskd; 2009 Mar; 153(11):503-7. PubMed ID: 19402326
[No Abstract] [Full Text] [Related]
6. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
Trimble EL; Thompson S; Christian MC; Minasian L
Oncologist; 2008 Apr; 13(4):403-9. PubMed ID: 18448554
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity and chemoresistance testing.
Markman M
J Clin Oncol; 2005 Oct; 23(29):7363-4. PubMed ID: 16210675
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells: a step toward the cure.
Boman BM; Wicha MS
J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
[No Abstract] [Full Text] [Related]
11. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Song YC; Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():26-34. PubMed ID: 17404014
[TBL] [Abstract][Full Text] [Related]
12. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
Larsen EP; Blaakaer J
Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling.
Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K
Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698
[TBL] [Abstract][Full Text] [Related]
14. [Anti-tumor activity of thymosterine].
Milcu SM; Potop I; Ghinea E
Endocrinologie; 1980; 18(4):235-8. PubMed ID: 6259708
[No Abstract] [Full Text] [Related]
15. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Markman M
Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
[TBL] [Abstract][Full Text] [Related]
16. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.
Kang S; Nam BH
Ann Surg Oncol; 2009 Aug; 16(8):2315-20. PubMed ID: 19517192
[TBL] [Abstract][Full Text] [Related]
17. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and non-apoptotic deaths in cancer development and treatment response.
de Bruin EC; Medema JP
Cancer Treat Rev; 2008 Dec; 34(8):737-49. PubMed ID: 18722718
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy.
Puré E; Hingorani SR
Trends Cancer; 2018 Apr; 4(4):273-277. PubMed ID: 29606311
[TBL] [Abstract][Full Text] [Related]
20. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
